(Total Views: 550)
Posted On: 05/08/2025 4:56:06 PM
Post# of 157747
Thanks OHM. I really appreciate your expertise. Leronlimab numbers are still extremely impressive when compared to Trodelvy.
Grok after evaluating ASCENT data:
Conclusion:
Based on the Kaplan-Meier OS data from the ASCENT trial, 2 patients out of the 267 in the Trodelvy (sacituzumab govitecan) arm were still alive at exactly 30 months, as indicated by the "number at risk" at that time point. This is a direct and precise answer derived from the graph.
Grok after evaluating ASCENT data:
Conclusion:
Based on the Kaplan-Meier OS data from the ASCENT trial, 2 patients out of the 267 in the Trodelvy (sacituzumab govitecan) arm were still alive at exactly 30 months, as indicated by the "number at risk" at that time point. This is a direct and precise answer derived from the graph.
(4)
(0)
